Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is bullish on the stock ...
Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $19 price target After its IPO in September 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
